March 19th, 2018

Click here to begin reading
your complementary article

A Note from the Editor-in-Chief
Authors:  Lawrence D. Devoe, M.D.
  Welcome to the May-June 2017 Editor-in-Chief’s page. This editorial column focuses on implications for patients and healthcare providers following the recent decision by the US Food and Drug Administration (FDA) to grant approval for direct-to-consumer (DTC) genetic health risk screening. The Editor would like to thank Mark I. Evans, M.D., Comprehensive Genetics, New York, NY, for his
assistance in the preparation of this column.
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from